Effect of right ventricle mid-septum selective site pacing in 133 pediatric patients
李璟昊,刘海菊,张仪,江河,李小梅,李梅婷
DOI: https://doi.org/10.3760/cma.j.cn.113859-20210526-00124
2021-01-01
Abstract:Objective:To systematically evaluate the safety and efficacy of active fixation lead (3830) for selective site pacing in pediatric patients.Methods:In Division of Pediatric Cardiology, Heart Center, First Hospital of Tsinghua University, from June 2015 to December 2019, in 133 patients, active fixation lead (3830) were implanted at the right ventricular septum selective site, including 45 with congenital heart disease (45/133, 33.8%) . The mean age at implantation was (5.9±4.5) years, mean body weight was (23.2±14.9) kg. The success and safety of implant procedures, the parameters of leads and cardiac function were observed during follow-up.Results:All of the 133 patients, 132 (132/133, 99.2%) were successfully implanted active fixation lead (3830) in right ventricular septum region. The mean fluoroscopy time was (2.5±2.7) min, the mean fluoroscopy exposing dose (5.0±3.7) mGy and the mean procedural time (93.5±36.3) min. Except for acute lead dislodgement in one patient who was repositioned successfully, no complications occurred during the follow-up, including pocket infection, cardiac perforation, late dislodgement, lead fracture, phrenic nerve stimulation and venous thrombosis, et al. During the (23.2±15.6) months of follow-up, the electrical performance of active fixation lead (3830) showed stable. Compared to that at the procedure, the mean pacing threshold slightly increased during the follow-up[ (1.25±0.89) V vs. (0.52±0.23) V, P<0.05) ], sensing values were not shifted[ (12.56±4.29) mV vs. (13.26±5.22) mV, P=0.076], the mean impedance slightly decreased[ (550.7±117.2) Ω vs. (680.2±114.2) Ω, P<0.05]. The mean pacing QRS duration after implantation was (110.9±10.65) ms. Both left ventricular ejection fraction (LVEF) and left ventricular end diastolic diameter (LVEDD) showed no significant difference before and after implantation during the follow-up[LVEF 64%±8% vs. 65%±4%, P=0.376; LVEDD (40.21±7.17) mm vs. (40.69±5.93) mm, P=0.172]. Conclusion:Active fixation lead (3830) is efficacious and safe for transvenous selective site pacing (right ventricle mid-septum) in pediatric patients. At mid and long-term follow-up, electrical and mechanical performance is optimal. Pacing in right ventricle mid-septum could preserve normal cardiac function in pediatric patients.